The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO WCGIC 2023 | ACT4: reducing radiotherapy doses to improve outcomes in anal cancer
Sheela Rao, MBBS, FRCP, MD (Res), Royal Marsden Hospital, London, UK, discusses current trials in the field of anal cancer. The ACT4 trial (CRUK/15/007) aims to reduce radiotherapy doses to improve patient outcomes. The initial data from this trial is encouraging and suggests more favorable patient outcomes with a comparable clinical and MRI complete response (CR). Current ongoing trials are researching the effects of combining chemotherapy with immunotherapy. This interview took place at the ESMO World Congress on Gastrointestinal Cancer (WCGIC) 2023 in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
